Fig. 6From: Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trialCorrelation of sputum NSPs in separate dosing arms at Week 4. NSP sputum correlation analysis was performed for placebo, 10 mg brensocatib and 25 mg brensocatib. Simple linear regression was plotted with the best-fit line plus 95% confidence intervalsBack to article page